Skip to main content

MAIA Biotechnology, Inc.

MAIA
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001878313

In the last 90 days, MAIA Biotechnology, Inc. insiders filed 7 open-market purchases and 0 sales; 43 institutions reported holding it in 13F filings for Q3 2026, worth $14.2M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 10, 2026, 1:20 AM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of MAIA Biotechnology, Inc., annual
Line itemFY2025FY2024FY2023FY2022
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Filing10-K10-K10-K10-K
Reported–––Mar 24, 2023
Revenue–$0$0$0
Operating expenses$24.3M$17.0M$20.2M$16.2M
Research and development$453.7K$10.0M$11.1M$8.93M
Selling, general and administrative$9.72M$6.95M$9.07M$6.14M
Operating income-$24.3M-$17.0M-$20.2M-$16.2M
Interest expense–$57$6.86K$6.97K
Income tax$2.00K–––
Net income-$22.4M-$23.3M-$19.8M-$15.8M
EPS, basic$-0.70$-1.05$-1.49$-1.75
EPS, diluted$-0.70$-1.05$-1.49$-1.75
Weighted shares, basic32.1M22.2M13.3M9.28M
Weighted shares, diluted32.1M22.2M13.3M9.28M

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of MAIA Biotechnology, Inc., annual
Line itemFY2025FY2024FY2023FY2022
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Filing10-K10-K10-K10-K
Reported–––Mar 24, 2023
Cash and equivalents$0$0$0$0
Total current assets$9.70M$10.2M$7.56M$11.8M
Total assets$9.70M$10.2M$7.57M$12.0M
Accounts payable$2.04M$1.51M$1.64M$1.17M
Total current liabilities$5.84M$3.83M$4.94M$3.27M
Total liabilities$7.33M$6.52M$7.09M$3.51M
Shareholders' equity$2.38M$3.63M$477.5K$8.51M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of MAIA Biotechnology, Inc., annual
Line itemFY2025FY2024FY2023FY2022
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Filing10-K10-K10-K10-K
Reported–––Mar 24, 2023
Operating cash flow-$18.8M-$15.7M-$13.1M-$11.7M
Stock-based compensation$2.63M$1.91M$3.09M$2.32M
Financing cash flow$17.9M$18.2M$9.27M$12.0M
Net change in cash–$2.45M-$3.80M$376.6K

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for MAIA Biotechnology, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 9, 202661.8M+66.7%SEC
Aug 10, 202660.8M+84.4%SEC
May 11, 202660.8M+100.6%SEC
Mar 23, 202660.7M+105.1%SEC
Nov 7, 202537.0M+46.2%SEC
Aug 11, 202533.0M+38.0%SEC
May 9, 202530.3M+38.8%SEC
Mar 21, 202529.6M+47.9%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.